Our previous research demonstrated that Proteoglycan-4 (PRG4) enhances the anti-proliferative effect of the multi-kinase inhibitor regorafenib in simple in vitro two-dimensional HCC models. This evidence concerns the gene PRG4 and hepatocellular carcinoma.